PhRMA

Representing America’s biopharma & biotech companies. Shaping policy so science thrives & patients benefit.

📱Text JOIN to 254506

[PhRMA @PhRMA]

Patients are counting on the next breakthrough and you can help make it happen when you text JOIN to 254506 🔬✨

[PhRMA @PhRMA]

Retired Air Force Lt. Col. Ken served his country for years. In 2019, he faced a new fight when he was diagnosed with early stage prostate cancer.

Thanks to medical innovation, Ken won his battle against cancer and maintained his quality of life.

Learn more at https://t.co/w3Yfl5ZxkJ

[PhRMA @PhRMA]

What does a place like Houston have to do with global biopharmaceutical competition with China? Rice Biotech Launchpad’s Paul Wotton lays it out.

Watch the @axios Live clip from the Houston event 🔊

https://t.co/Yulc1GJAzs

[PhRMA @PhRMA]

$142 BILLION. $142,000,000,000. That’s how much hospitals, clinics and their for-profit partners pocketed from 340B medicine markups in 2025.

Learn more at https://t.co/0C6DKNkUyA.

[PhRMA @PhRMA]

Our mandate is to advance and protect the American biopharmaceutical industry while championing policies that help patients access the medicines they need. To accomplish these goals, we need to have a strong, decisive leadership team. We're pleased to announce two important additions to PhRMA's leadership team.

Kristi Way has joined PhRMA as Senior Executive Vice President, Head of Strategy and Operations. Kristi brings decades of leadership experience across government, business and strategic operations, most recently at Moelis & Company. She previously served as Chief of Staff and Senior Advisor to Eric Cantor during his tenure in Congress.

Michael Woody has been promoted to Executive Vice President, Federal Advocacy. Mike brings more than 20 years of experience in federal health policy, including ​as a senior health policy advisor to Former Senator Tom Harkin (D-IA) on the Senate HELP Committee. Since returning to PhRMA in 2022, he has played a key role in strengthening our bipartisan engagement on Capitol Hill and advancing policies that support patients and American innovation.

​Together, Mike and Kristi will play important roles in advancing PhRMA’s mission providing patients access to life saving and life changing medicines while in pursuit of more American innovation.

Congratulations Kristi and Mike!

[PhRMA @PhRMA]

From efficient clinical trials to training the workforce for companies like @EliLillyandCo and @bmsnews, Houston has all the elements for biopharmaceutical innovation.

Watch to learn more 🎥

[PhRMA @PhRMA]

American innovation created continuous glucose monitors, a breakthrough that made diabetes manageable for kids and adults. For moms like Flora, who know what it’s like to have a kid with Type 1 diabetes, they’re waiting for the next breakthrough – a cure for diabetes.

It’s up to Washington to make sure we keep our biopharmaceutical edge.

[PhRMA @PhRMA]

American leadership in vaccine innovation strengthens both national security and public health. We must protect this leadership.

Learn more: https://t.co/7QRowaMcNT

[PhRMA @PhRMA]

With over 8,000 innovative medicines in development, America’s strong IP protections help fuel groundbreaking treatment advances while balancing affordability. Learn more: https://t.co/horlNXp9Wf

[PhRMA @PhRMA]

Certain peptides, often referred to as “wellness peptides,” have not been subject to the FDA’s gold-standard review for approval and their safety and effectiveness have not been established in clinical trials.

Get the truth behind the latest health and wellness influencer trend: https://t.co/71YWDSSbbr

[PhRMA @PhRMA]

“We’ve got a workforce that’s ambitious, young, diverse.” Greater Houston Partnership President and CEO Steve Kean on why Houston is ready to win more biopharmaceutical research and innovation.

https://t.co/3FSOKFbbuF

[PhRMA @PhRMA]

@bmsnews didn’t invest in Houston by accident.

Watch the clip to hear from BMS’ Cari Gallman on the 3️⃣ reasons they chose 📍Houston and read more: https://t.co/QQ5ZdqVxu1

[PhRMA @PhRMA]

A GLP-1 saved Stacie’s life. We can’t jeopardize America’s innovation ecosystem that makes breakthroughs like this possible.

Tell Washington: Keep America in the lead.

https://t.co/8yCnxu0oXq

[PhRMA @PhRMA]

Why Houston? Cari Gallman of @bmsnews says it’s the perfect ecosystem for turning research into new treatments for patients, and that’s why BMS is investing $2.3B there. Learn more ⬇️

https://t.co/PSGxfPCksH

[PhRMA @PhRMA]

☠️𝐁𝐎𝐍𝐄-𝐂𝐇𝐈𝐋𝐋𝐈𝐍𝐆 𝐑𝐄𝐏𝐎𝐑𝐓: Hospitals, clinics and their for-profit partners pocketed $142B in 2025 from 340B medicine markups.

The more big hospital systems exploit the program for profit, the more it increases costs for everyone. See the report: https://t.co/usLxn5gtC4

[PhRMA @PhRMA]

PBMs control almost 80% of the prescription drug market. That’s scarier than any costume you’ll see today.

👻 Don’t let middlemen haunt your pharmacy bill.

Learn more: https://t.co/RVCz3TJtJh

[PhRMA @PhRMA]

Up to 500 FEWER treatments and cures in the next decade. That’s what’s at stake if MFN pulls billions away from medical research.

Learn more: https://t.co/zWAL6OZBlr

[PhRMA @PhRMA]

Yesterday was a special day for the people behind the science in New Jersey.

Biopharmaceutical researchers participating in PhRMA’s researcher fly-in were recognized on the Assembly floor for their contributions to scientific discovery, medical innovation and public health.

[PhRMA @PhRMA]

At @axios Live’s Beyond the Breakthrough in Richmond, leaders from government and industry joined Axios to discuss the continuing investments that will keep the area’s biopharma sector growing, from smart policies to workforce development. PhRMA was proud to sponsor the event!

Photo credits: Jen Danson for Axios

[PhRMA @PhRMA]

More than 1 million Americans now go to work every day to research, manufacture and deliver new medicines.

And it’s a 50-state story. Every state, DC and Puerto Rico is home to biopharma jobs.

That’s what American leadership in medicines looks like.

See what biopharma means for your state: https://t.co/bqzwcqGJjd